AmorChem backs research on central nervous system diseases
Canadian life sciences venture capital firm AmorChem has invested in a research program from Université Laval and the Research Center of the Centre Hospitalier Universitaire de Québec.
Canadian life sciences venture capital firm AmorChem has invested in a research program from Université Laval and the Research Center of the Centre Hospitalier Universitaire de Québec.
Copyright PEI Media
Not for publication, email or dissemination